{"id":6903,"date":"2023-02-08T15:38:28","date_gmt":"2023-02-08T10:38:28","guid":{"rendered":"https:\/\/www.serenepharma.com\/?p=6903"},"modified":"2023-02-08T15:38:31","modified_gmt":"2023-02-08T10:38:31","slug":"otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili","status":"publish","type":"post","link":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/","title":{"rendered":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2<\/p><p>Braunuald E., SGLT<sup>2<\/sup> ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765<\/p><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Asosiy ma\u2019lumotlar<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biz SGLT<sup>2<\/sup><sub>i<\/sub> qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya olgan bemorlarda yurak-qon tomir natijalari, buyrak funktsiyasi va diurezni solishtirishga harakat qildik.<br>O\u2019tkir yurak yetishmovchiligi (O\u2019YY) 65 yoshdan oshgan odamlarda rejadan tashqari kasalxonaga yotqizilishning asosiy sababidir va yangi paydo bo\u2019lishi yoki yurak etishmovchiligi (YY) belgilarining kuchayishi bilan tavsiflanadi. O\u2019YY bilan kasallangan bemorlarning aksariyati kasalxonaga suyuqlikning haddan tashqari yuklanishi belgilari bilan murojaat qilishadi va odatda simptomlarni yaxshilash va kasallanishni kamaytirish uchun tomir ichiga yuboriladigan diuretiklarning ortib boruvchi dozalari bilan davolanadi. Shu bilan birga, diuretiklarni qabul qilishning ushbu rejimi buyrak funktsiyasining yomonlashishi bilan cheklangan va ko\u2019plab bemorlar O\u2019YY uchun kasalxonada bo\u2019lganlarida etarli darajada shishga qarshi davo. Darhaqiqat, so\u2019nggi o\u2019n yilliklarda zamonaviy O\u2019YY davolash sezilarli darajada o\u2019zgarmadi. Uyga javob berishdan keyingi natijalar qoniqarsiz bo\u2019lib qolishi ajablanarli emas: 30 kunlik readmissiya va 1 yillik o\u2019lim darajasi 20-30% ga etdi. Shuning uchun ushbu populyatsiyada yangi terapevtik strategiyalarga ehtiyoj qondirilmagan.<br>So\u2019nggi yillarda natriy-glyukoza kotransporter 2 (SGLT<sup>2<\/sup>) inhibit\u00f6rleri diabet yoki otib berish fraktsiyasi holatidan qat\u2019i nazar, yurak-qon tomir o\u2019limini va kasalxonaga yotqizishni kamaytirish uchun YYni davolashda samarali ekanligi isbotlangan. SGLT<sup>2<\/sup>, shuningdek, surunkali buyrak kasalligi (SBK) bo\u2019lgan bemorlarda yurak-qon tomir o\u2019limi yoki buyrak funktsiyasining yomonlashuvining umumiy natijasini kamaytiradi. Shu bilan birga, O\u2019YY bilan davolangan bemorlarda an\u2019anaviy diuretik terapiyaga SGLT<sup>2<\/sup> qo\u2019shilishining xavfsizligi va samaradorligi haqida kam narsa ma\u2019lum.<br>Ushbu masalani ko\u2019rib chiqqan avvalgi meta-tahlilda SGLT<sup>2<\/sup> bilan davolangan be-<br>morlarda YY uchun qayta kasalxonaga yotqizish kamayganligi aniqlandi. biroq, SGLT<sup>2<\/sup> bilan o\u2019limning sezilarli pasayishi kuzatilmadi, bu cheklangan quvvat bilan bog\u2019liq bo\u2019lishi mumkin. Shuning uchun biz O\u2019YY bilan og\u2019rigan bemorlarda yurak-qon tomir va buyrak yakuniy nuqtalari uchun an\u2019anaviy diuretik terapiyani SGLT<sup>2<\/sup> bilan yoki bo\u2019lmagan holda taqqoslaydigan randomizatsiyalangan nazorat ostida tekshiruvlarni (RCTs) yangilangan tizimli ko\u2019rib chiqish va meta-tahlil qilishni maqsad qildik.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Usullar va natijalar<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Uchta elektron ma\u2019lumotlar bazasini muntazam ravishda qidirish natijasida 2824 bemorni qamrab olgan to\u2019qqizta tegishli randomizatsiyalangan nazorat ostida tadqiqotlar aniqlandi. An\u2019anaviy O\u2019YY terapiyasiga SGLT<sup>2<\/sup> qo\u2019shilishi barcha sabablarga ko\u2019ra o\u2019limning pasayishiga olib keldi (koeffitsientlar nisbati [OR] 0.75; 95% CI 0.56\u20130.99; p = 0.049), yurak etishmovchiligi (YY) uchun qayta kasalxonaga yotqizish (OR 0.54; 95% CI 0.44-0.66; p &lt; 0.001) va kumulyativ yurak-qon tomir kasalliklaridan o\u2019lim va YY uchun qayta kasalxonaga yotqizish (xavf darajasi 0.71; 95% CI 0.60\u20130.84; p &lt; 0.001). Bundan tashqari, SGLT<sup>2<\/sup> siydikning o\u2019rtacha kunlik hajmini litrda oshirdi (o\u2019rtacha farq [MD] 0.45; 95% CI 0.03\u20130.87; p = 0.035) va halqali diuretiklarning o\u2019rtacha kunlik dozalarini mg furosemid ekvivalentiga kamaytirdi (MD -34.90; 95% CI [\u2212 52.58, \u2212 17.21]; p &lt; 0.001) buyrak funktsiyasining yomonlashishi chastotasining oshishi kuzatilmadi(OR 0.75; 95% CI 0.43\u20131.29; p \\ u003d 0.290).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Xulosa<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">An\u2019anaviy diuretik terapiyaga SGLT<sup>2<\/sup> qo\u2019shilishi barcha sabablarga ko\u2019ra o\u2019limni, YY uchun qayta kasalxonaga yotqizishni va yurak-qon tomir kasalliklari uchun barcha sabablarga ko\u2019ra o\u2019limni yoki YY uchun qayta kasalxonaga yotqizishni kamaytirdi. Bundan tashqari, SGLT<sup>2<\/sup> past dozali diuretiklar bilan yuqori diurez hajmi bilan bog\u2019liq.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><a href=\"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1.png\"><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1-1024x411.png\" alt=\"\" class=\"wp-image-6904\" width=\"528\" height=\"212\" srcset=\"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1-1024x411.png 1024w, https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1-300x120.png 300w, https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1-768x308.png 768w, https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1-600x241.png 600w, https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1.png 1362w\" sizes=\"(max-width: 528px) 100vw, 528px\" \/><\/a><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><strong>SGLT<sup>2<\/sup> haqida ba\u2019zi faktlar<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">2012 yildan 2015 yilgacha Evropa tibbiyot agentligi (EMA) va AQSh oziq-ovqat va farmatsevtika idorasi (FDA) T2DM bilan kasallangan odamlarda plazmadagi glyukoza miqdorini pasaytirish uchun uchta SGLT<sup>2<\/sup><sub>i<\/sub>s, dapagliflozin, kanagliflozin va empagliflozinni tasdiqladi<br>SGLT<sup>2<\/sup> nafaqat glyukozuriyani keltirib chiqaradi, balki yurak etishmovchiligining rivojlanishi va zo\u2019rayishini kamaytiradi va T2DM va chap qorincha otib berish fraktsiyasi kamaygan bemorlarda umrini uzaytiradi<br>SGLT<sup>2<\/sup> T2DM mavjudligi yoki yo\u2019qligidan qat\u2019i nazar, HFrEF bilan og\u2019rigan bemorlarning natijalarini yaxshilaydi va shu bilan ushbu dorilar uchun potentsial maqsadli guruhni sezilarli darajada kengaytiradi.<br>SGLT<sup>2<\/sup> surunkali yurak yetishmovchiligi bo\u2019lgan bemorlarda turli xil otib berish fraktsiyalarida foydali bo\u2019lib, maqsadli aholini yanada kengaytiradi.<br>SGLT<sup>2<\/sup> surunkali buyrak kasalligi bo\u2019lgan bemorlarda buyrak kasalligining so\u2019nggi bosqichini rivojlanish xavfini kamaytiradi. Hozirgi vaqtda T2DM bo\u2019lmagan, ammo turli xil surunkali buyrak kasalliklari bo\u2019lgan bemorlarda SGLT<sup>2<\/sup> ning foydalari o\u2019rganilmoqda.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya&#8230;<\/p>\n","protected":false},"author":1,"featured_media":6906,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rs_blank_template":"","rs_page_bg_color":"","slide_template_v7":"","inline_featured_image":false,"footnotes":""},"categories":[141],"tags":[160],"class_list":["post-6903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gazetauz","tag-kardiologiya"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"serene_admin\"\/>\n\t<meta name=\"google-site-verification\" content=\"E4w7Tq5OUsX4iPrZpEh5w3x9S4TTbvbUSzx6c5DiiDY\" \/>\n\t<meta name=\"yandex-verification\" content=\"4d7ed8a4cfca7240\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"uz_UZ\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Serene - The Leading Pharmaceutical Company in Central Asia\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene\" \/>\n\t\t<meta property=\"og:description\" content=\"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/serene_logo_sticky.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/serene_logo_sticky.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"83\" \/>\n\t\t<meta property=\"og:image:height\" content=\"80\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-02-08T10:38:28+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2023-02-08T10:38:31+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Serenepharma\/\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/serene_logo_sticky.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#blogposting\",\"name\":\"O\\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\\u2019llanilishining yurak-qon tomir va buyrak ta\\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene\",\"headline\":\"O\\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\\u2019llanilishining yurak-qon tomir va buyrak ta\\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili\",\"author\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/author\\\/serene_admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/8uz1.png\",\"width\":1362,\"height\":546},\"datePublished\":\"2023-02-08T15:38:28+05:00\",\"dateModified\":\"2023-02-08T15:38:31+05:00\",\"inLanguage\":\"uz-UZ\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#webpage\"},\"articleSection\":\"Gazeta, Kardiologiya, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/category\\\/gazetauz\\\/#listItem\",\"name\":\"Gazeta\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/category\\\/gazetauz\\\/#listItem\",\"position\":2,\"name\":\"Gazeta\",\"item\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/category\\\/gazetauz\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#listItem\",\"name\":\"O\\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\\u2019llanilishining yurak-qon tomir va buyrak ta\\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#listItem\",\"position\":3,\"name\":\"O\\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\\u2019llanilishining yurak-qon tomir va buyrak ta\\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/category\\\/gazetauz\\\/#listItem\",\"name\":\"Gazeta\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#organization\",\"name\":\"Serene\",\"description\":\"The Leading Pharmaceutical Company in Central Asia\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/\",\"telephone\":\"+998782910140\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/logo-.png\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#organizationLogo\",\"width\":286,\"height\":120},\"image\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/Serenepharma\\\/\",\"https:\\\/\\\/www.instagram.com\\\/serene_group_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/author\\\/serene_admin\\\/#author\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/author\\\/serene_admin\\\/\",\"name\":\"serene_admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/64ce6ede9180be17e1a7dac397b0fac976d02c34990350fde5853b7af19b7c70?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"serene_admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#webpage\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/\",\"name\":\"O\\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\\u2019llanilishining yurak-qon tomir va buyrak ta\\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene\",\"description\":\"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \\\/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\\\/\\\/doi.org\\\/10.1007\\\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\\u20131030, https:\\\/\\\/doi.org\\\/10.1093\\\/eurheartj\\\/ehab765 Asosiy ma\\u2019lumotlar Biz SGLT2i qo\\u2019shilgan yoki qo\\u2019shilmagan o\\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya\",\"inLanguage\":\"uz-UZ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/author\\\/serene_admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/author\\\/serene_admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/8uz1.png\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#mainImage\",\"width\":1362,\"height\":546},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/gazetauz\\\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\\\/#mainImage\"},\"datePublished\":\"2023-02-08T15:38:28+05:00\",\"dateModified\":\"2023-02-08T15:38:31+05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#website\",\"url\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/\",\"name\":\"Serene\",\"description\":\"The Leading Pharmaceutical Company in Central Asia\",\"inLanguage\":\"uz-UZ\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.serenepharma.com\\\/uz\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene","description":"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya","canonical_url":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"E4w7Tq5OUsX4iPrZpEh5w3x9S4TTbvbUSzx6c5DiiDY","yandex-verification":"4d7ed8a4cfca7240","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#blogposting","name":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene","headline":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili","author":{"@id":"https:\/\/www.serenepharma.com\/uz\/author\/serene_admin\/#author"},"publisher":{"@id":"https:\/\/www.serenepharma.com\/uz\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1.png","width":1362,"height":546},"datePublished":"2023-02-08T15:38:28+05:00","dateModified":"2023-02-08T15:38:31+05:00","inLanguage":"uz-UZ","mainEntityOfPage":{"@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#webpage"},"isPartOf":{"@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#webpage"},"articleSection":"Gazeta, Kardiologiya, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/#listItem","position":1,"name":"Home","item":"https:\/\/www.serenepharma.com\/uz\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/category\/gazetauz\/#listItem","name":"Gazeta"}},{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/category\/gazetauz\/#listItem","position":2,"name":"Gazeta","item":"https:\/\/www.serenepharma.com\/uz\/category\/gazetauz\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#listItem","name":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#listItem","position":3,"name":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili","previousItem":{"@type":"ListItem","@id":"https:\/\/www.serenepharma.com\/uz\/category\/gazetauz\/#listItem","name":"Gazeta"}}]},{"@type":"Organization","@id":"https:\/\/www.serenepharma.com\/uz\/#organization","name":"Serene","description":"The Leading Pharmaceutical Company in Central Asia","url":"https:\/\/www.serenepharma.com\/uz\/","telephone":"+998782910140","logo":{"@type":"ImageObject","url":"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/logo-.png","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#organizationLogo","width":286,"height":120},"image":{"@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#organizationLogo"},"sameAs":["https:\/\/www.facebook.com\/Serenepharma\/","https:\/\/www.instagram.com\/serene_group_\/"]},{"@type":"Person","@id":"https:\/\/www.serenepharma.com\/uz\/author\/serene_admin\/#author","url":"https:\/\/www.serenepharma.com\/uz\/author\/serene_admin\/","name":"serene_admin","image":{"@type":"ImageObject","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/64ce6ede9180be17e1a7dac397b0fac976d02c34990350fde5853b7af19b7c70?s=96&d=mm&r=g","width":96,"height":96,"caption":"serene_admin"}},{"@type":"WebPage","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#webpage","url":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/","name":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene","description":"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya","inLanguage":"uz-UZ","isPartOf":{"@id":"https:\/\/www.serenepharma.com\/uz\/#website"},"breadcrumb":{"@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#breadcrumblist"},"author":{"@id":"https:\/\/www.serenepharma.com\/uz\/author\/serene_admin\/#author"},"creator":{"@id":"https:\/\/www.serenepharma.com\/uz\/author\/serene_admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2023\/02\/8uz1.png","@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#mainImage","width":1362,"height":546},"primaryImageOfPage":{"@id":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/#mainImage"},"datePublished":"2023-02-08T15:38:28+05:00","dateModified":"2023-02-08T15:38:31+05:00"},{"@type":"WebSite","@id":"https:\/\/www.serenepharma.com\/uz\/#website","url":"https:\/\/www.serenepharma.com\/uz\/","name":"Serene","description":"The Leading Pharmaceutical Company in Central Asia","inLanguage":"uz-UZ","publisher":{"@id":"https:\/\/www.serenepharma.com\/uz\/#organization"}}]},"og:locale":"uz_UZ","og:site_name":"Serene - The Leading Pharmaceutical Company in Central Asia","og:type":"article","og:title":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene","og:description":"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya","og:url":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/","og:image":"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/serene_logo_sticky.png","og:image:secure_url":"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/serene_logo_sticky.png","og:image:width":83,"og:image:height":80,"article:published_time":"2023-02-08T10:38:28+00:00","article:modified_time":"2023-02-08T10:38:31+00:00","article:publisher":"https:\/\/www.facebook.com\/Serenepharma\/","twitter:card":"summary","twitter:title":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili - Serene","twitter:description":"Carvalho P. va boshq., Kardiologiyada klinik tadqiqotlar, Olingan: 2022 yil 22 sentyabr \/ qabul qilingan: 2022 yil 21 dekabr, 2023 yil 2 yanvarda onlayn nashr etilgan, https:\/\/doi.org\/10.1007\/s00392-022-02148-2 Braunuald E., SGLT2 ingibitorlari: 21-asr statinlari, Evropa Yurak Jurnali (2022) 43, 1029\u20131030, https:\/\/doi.org\/10.1093\/eurheartj\/ehab765 Asosiy ma\u2019lumotlar Biz SGLT2i qo\u2019shilgan yoki qo\u2019shilmagan o\u2019tkir yurak etishmovchiligi (AHF) uchun standart diuretik terapiya","twitter:image":"https:\/\/www.serenepharma.com\/wp-content\/uploads\/2022\/02\/serene_logo_sticky.png"},"aioseo_meta_data":{"post_id":"6903","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2026-02-11 16:46:29","updated":"2026-02-11 16:46:29","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.serenepharma.com\/uz\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.serenepharma.com\/uz\/category\/gazetauz\/\" title=\"Gazeta\">Gazeta<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tO\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.serenepharma.com\/uz\/"},{"label":"Gazeta","link":"https:\/\/www.serenepharma.com\/uz\/category\/gazetauz\/"},{"label":"O\u2019tkir yurak etishmovchiligida SGLT2 inhibitori qo\u2019llanilishining yurak-qon tomir va buyrak ta\u2019siri: randomizatsiyalangan nazorat ostida sinovlarning meta-tahlili","link":"https:\/\/www.serenepharma.com\/uz\/gazetauz\/otkir-yurak-etishmovchiligida-sglt2-inhibitori-qollanilishining-yurak-qon-tomir-va-buyrak-tasiri-randomizatsiyalangan-nazorat-ostida-sinovlarning-meta-tahlili\/"}],"_links":{"self":[{"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/posts\/6903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/comments?post=6903"}],"version-history":[{"count":0,"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/posts\/6903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/media\/6906"}],"wp:attachment":[{"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/media?parent=6903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/categories?post=6903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.serenepharma.com\/uz\/wp-json\/wp\/v2\/tags?post=6903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}